Researchers have identified a key mechanism that allows small cell lung cancer (SCLC) to return after initial treatment. The study reveals that certain cancer cells enter a dormant, drug-resistant state, enabling them to survive chemotherapy and later trigger a relapse. This discovery, involving specific cellular pathways, provides a new target for developing therapies aimed at preventing recurrence and improving long-term survival rates for patients with this aggressive cancer. Read the full article at https://www.sciencedaily.com/releases/2026/03/260325005917.htm